Low-molecular-weight heparin in arterial reconstructive surgery: A double-blind, randomized dose-finding trial

Clinical and Applied Thrombosis/Hemostasis

Volumn 8, Issue 4, 2002, Pages 337-345

  Kujath, Peter ^a   Eckmann, Christian ^a   Misselwitz, Frank ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Arterial reconstructive surgery; Bleeding; Dose finding; Early reocclusion; Graft patency; Low molecular weight heparin; Reviparin

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN;

ADULT; AGED; ANGIOGRAPHY; ANTICOAGULATION; ARTERY RECONSTRUCTION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT PATENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0036818802     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960200800405     Document Type: Article

References (26)

1. Clagett GP, Genton E, Salzman EW. Antithrombotic therapy in peripheral vascular diseases (5th ACCP Conference on Antithrombotic Therapy). Chest 1998;114:666S.
2. Wakefield TW, Lindblad B, Stanley TJ, et al. Heparin and protamine use in peripheral vascular surgery: A comparison between surgerons of the Society for Vascular Surgery and the European Society for Vascular Surgery. Eur J Vasc Surg 1994;8:193.
3. McMillan WD, McCarthy WJ, Lin SJ, et al. Perioperative low molecular weight heparin for infrageniculate bypass. J Vasc Surg 1997;25:796.
4. Alimi YS, Juhan C, Barthelemi P, et al. Evaluation of low molecular weight heparin during and after aortic and carotid surgery: Dose finding study. Panminerva Med 1996;38:15.
5. Samama CM, Gigou F III. Low molecular weight heparin in femorodistal reconstructive surgery: A multicenter open randomized study. Ann Vasc Surg 1995;9 [Suppl]:S45.
6. Samama CM. Enoxaparine versus non-fractionated heparin during vascular reconstruction therapy: An open multicenter randomized study. Ann Fr Anesth Reanim 1993;12 [Suppl]:R190.
7. Samama CM, Barre E, Combe S, et al. A pilot study on the use of a low molecular weight heparin (enoxaparin) in arterial reconstructive surgery. Semin Thromb Hemost 1991;17:367.
8. Melissari E, Stringer MD, Kakkar VV. The effect of a bolus of unfractionated or low molecular weight heparin during aortofemoral bypass grafting. Eur J Vasc Surg 1989;3:121.
9. Swedenborg J, Nydahl S, Egberg N. Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery. Eur J Endovasc Surg 1996;11:59.
10. Edmondson RA, Cohen AT, Das SK, et al. Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344:914.
11. Benedetti-Valentini F, Irace L, Gatusso R, et al. Arterial repair of the lower limbs: Prevention of prosthetic graft occlusion by LMW-heparin. Int Angiol 1988;7:29.
12. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330.
13. Lindhoff-Last E, Eichler P, Stein M, et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000;97:387.
14. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996;28:1437.
15. Preisack MB, Karsch KR. Low molecular weight heparin in prevention of restenosis after PTCA. Thromb Res 1996;81:53.
16. Oberhoff M, Bohnet A, Miljak T, et al. Efficacy of local low molecular weight heparin delivery using the dispatch catheter. Eur Heart J 1996;17:370.
17. Waibel P. Prognose arterieller rekonstruktionen bei PAVK. Vasa 1992;21:39.
18. Waibel P. Unterschied der Prognosen aortoiliakaler und femoropoplitealer Rekonstruktionen bei PAVK. Vasa 1993;22:26.
19. Waibel P. Unterschied der Prognosen arterieller Rekonstruktionen bei PAVK Stadium II und IV. Vasa 1992;21:46.
20. Waibel P. Antikoagulation nach arterieller Rekonstruktion bei PAVK. Vasa 1993;22:320.
21. Xiao Zihui, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low molecular weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251.
22. Strecker EP, Göttmann D, Boos I, et al. Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: Preliminary results of an ongoing study. Cardiovasc Intervent Radiol 1998;21:375.
23. Witt P, Patscheke H. Blutungszeit - Standortbestimmung. Hämostaseologie 1997;17:212.
24. Bandyk DF, Kaebnick HW, Stewart GW, et al. Durability of the in situ saphenous vein arterial bypass: A comparison of primary and secondary patency. J Vasc Surg 1987;5:256.
25. Abbott WM, Green RM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: Results of a multicenter randomized prospective trial. J Vasc Surg 1997;25:19.
26. Millaire A, DeGroote P, Decoulx E, et al. Long-term follow-up after peripheral and coronary angioplasty in patients undergoing both types of procedures. Angiology 1994;45:923.